These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18989773)

  • 1. Introduction: Vasopressin therapy.
    Whellan DJ
    Heart Fail Rev; 2009 Jun; 14(2):57-8. PubMed ID: 18989773
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyponatremia in heart failure.
    Farmakis D; Filippatos G; Parissis J; Kremastinos DT; Gheorghiade M
    Heart Fail Rev; 2009 Jun; 14(2):59-63. PubMed ID: 18758941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVP receptor antagonists in patients with CHF.
    Kumar SK; Mather PJ
    Heart Fail Rev; 2009 Jun; 14(2):83-6. PubMed ID: 18766439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Where vaptans do and do not fit in the treatment of hyponatremia.
    Jovanovich AJ; Berl T
    Kidney Int; 2013 Apr; 83(4):563-7. PubMed ID: 23254896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 6. Vasopressin receptor antagonists.
    Greenberg A; Verbalis JG
    Kidney Int; 2006 Jun; 69(12):2124-30. PubMed ID: 16672911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.
    Sahu R; Balaguru D; Thapar V; Haque I; Pham-Peyton C; Bricker JT
    Tex Heart Inst J; 2012; 39(5):724-6. PubMed ID: 23109779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome.
    Schrier RW; Masoumi A; Elhassan E
    Blood Purif; 2009; 27(1):28-32. PubMed ID: 19169014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyponatremia in heart failure: concluding remarks.
    Chatterjee K
    Heart Fail Rev; 2009 Jun; 14(2):87-8. PubMed ID: 18758942
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.
    Jao GT; Chiong JR
    Clin Cardiol; 2010 Nov; 33(11):666-71. PubMed ID: 21089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan for hyponatremia.
    Ozkan C; Kirkpantur A; Arici M
    N Engl J Med; 2007 Mar; 356(9):962; author reply 962-3. PubMed ID: 17338053
    [No Abstract]   [Full Text] [Related]  

  • 13. Tolvaptan for hyponatremia.
    Weise WJ; Rimmer JM; Hood VL
    N Engl J Med; 2007 Mar; 356(9):961; author reply 962-3. PubMed ID: 17329708
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyponatremia and outcomes in patients with heart failure.
    Goldsmith SR
    Heart; 2012 Dec; 98(24):1761-2. PubMed ID: 23204533
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyponatremia in heart failure: time for a trial.
    Goldsmith SR
    J Card Fail; 2013 Jun; 19(6):398-400. PubMed ID: 23743488
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
    Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin antagonists.
    Berl T
    N Engl J Med; 2015 Jun; 372(23):2207-16. PubMed ID: 26039601
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.